Pharmacological management of anticancer agent extravasation: A single institutional guideline.

about

Pharmacological management of anticancer agent extravasation: A single institutional guideline.

Item

http://www.wikidata.org/entity/Q47238461

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacological management of ...... ingle institutional guideline.

@en

Pharmacological management of ...... ingle institutional guideline.

@nl

type

Item

label

Pharmacological management of ...... ingle institutional guideline.

@en

Pharmacological management of ...... ingle institutional guideline.

@nl

prefLabel

Pharmacological management of ...... ingle institutional guideline.

@en

Pharmacological management of ...... ingle institutional guideline.

@nl

P1476

Pharmacological management of ...... ingle institutional guideline.

@en

P2093

Christina Mactal Haaf

http://www.w3.org/2001/XMLSchema#string

Jaime Kimmel

http://www.w3.org/2001/XMLSchema#string

Jennifer Anderson

http://www.w3.org/2001/XMLSchema#string

Patrick Fleming

http://www.w3.org/2001/XMLSchema#string

Sandra Cuellar

http://www.w3.org/2001/XMLSchema#string

P2860

Overview, prevention and management of chemotherapy extravasation

Dexrazoxane for the treatment of chemotherapy-related side effects.

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.

Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.

Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.

Anthracycline extravasation injuries: management with dexrazoxane.

Management of extravasation injuries: a focused evaluation of noncytotoxic medications.

The management of cytotoxic chemotherapy extravasation: a systematic review of the literature to evaluate the evidence underpinning contemporary practice.

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.

P304

1078155217690924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217690924

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29284352

http://www.w3.org/2001/XMLSchema#string